Black Diamond TherapeuticsBDTX
Recorded

Black Diamond Therapeutics Stifel 2026 Healthcare Conference

Review the key takeaways and the transcript of this earnings call.

Period 2026Duration29 minParticipants2

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Laura PrendergastAnalyst

All right. I am here with Black Diamond Therapeutics CEO, Mark. Mark, anything new today? Lots new today.

Mark VellecaCEO

Really great to be here at the Stifel conference after disclosing new data from our phase II trial and a really positive outcome from our end-of-phase II meeting with the FDA. I will enjoy chatting with you for the next 30 minutes. Maybe I will just start real quickly with about silevertinib and what it is.

Laura PrendergastAnalyst

Yeah, absolutely. Want to summarize the update that you guys gave today and- Yeah the drug, and then briefly, and then we can get more into Q&A as well.

Mark VellecaCEO

Sure. silevertinib is what we believe a best-in-class fourth-generation EGFR TKI. I think everyone here knows the drug TAGRISSO, osimertinib, which treats about three-quarters of EGFR mutant non-small cell lung cancer patients quite well. Obviously, that drug does very well for AstraZeneca. I think what we've learned in the space, in the EGFR mutant non-small cell lung cancer space, especially over the last three or four years, is that while EGFR TKIs can control disease very well in the thorax in lung cancer, most of these patients progress in the brain. Many of these patients present with brain metastases. There's something about EGFR mutant non-small cell lung cancer where it likes to go to the brain, and that's ultimately when patients progress on therapy, even with drugs like osimertinib. Our drug was designed from the get-go to be highly brain penetrant, and it is.

Mark VellecaCEO

We believe it is the most brain penetrant of any EGFR TKI. It also addresses not only these classical mutations that TAGRISSO goes after, but this other quarter of EGFR mutations, which is over 50 of them. They're often called atypical or uncommon, rare, but as a group, they're actually 25% of the population. Our drug very potently targets all of them, all 50-plus of those, unlike osimertinib, which does not have potent activity. We've been developing this drug for the last two years in this frontline patient population. It's a phase II trial, 43 patients, conducted primarily in the U.S., a few sites in Canada.

Mark VellecaCEO

We had an oral presentation at ASCO, and today we have now data, mature data, that I think we'll get into, that led to a highly positive end-of-phase II meeting with the FDA, where we now have a very clear path to accelerated approval, and capturing that entire non-classical mutation population.

Laura PrendergastAnalyst

I think, perhaps as an Analyst, one of the most exciting parts for me about that was that we no longer have to break down all the atypicals into all these rigorously defined little subgroups. It seems like if you don't have a classical mutation, if you don't have an exon 20 mutation, you can be enrolled in this trial.

Mark VellecaCEO

That's right, and I think there's been some confusion. Our Chief Medical Officer, and he said this in our call this morning, calls it alphabet soup of mutations because there's so many of them. If you think about a prescribing physician, they get the NGS report. The first page says you have a classical mutation, L858R exon 19 del. Every doc knows what to do with that. You prescribe osimertinib. Exon 20 insertions, definitely some more treatment options like RYBREVANT. Then they get to the second page, and there's this laundry list of mutations, and they don't have a drug. There are a couple of competitors that are developing drugs in this space. They're focusing on a subset of those mutations called PACC, and that is confusing too, because what's PACC, what's not?

Mark VellecaCEO

Our definition, agreed to by the FDA, is any mutation that's not a classical mutation or an exon 20 insertion.

Laura PrendergastAnalyst

Home run. Makes it a lot easier.

Mark VellecaCEO

Makes it a lot easier to enroll a trial, because all these patients are getting NGS testing. It's like, "Oh, you don't have a TAGRISSO mutation? Come onto the trial." As a prescribing physician, ultimately, in the label, very easy to understand.

Laura PrendergastAnalyst

As far as the phase III, in addition to having this broad group of EGFR mutant lung, you are focusing in on patients with brain metastases. Unlike some of the competitors that you just referred to, you guys have discussed with the FDA potential for an accelerated approval path based on CNS ORR. Competitors are focusing on systemic ORR. Can you speak to the de-risking involved with using a CNS ORR relative to systemic?

Mark VellecaCEO

Yeah. We can talk about why we are so confident that we can win in that patient population and still cover patients without brain metastases with this novel design. First, let us talk about CNS ORR as an endpoint. It has been used for many primary CNS tumors. It is actually, while it is not in the indication statement for tucatinib, it is a breast cancer drug, they do use CNS ORR for, is it in the label? The FDA issued guidance in 2020 for CNS active drugs. There are separate criteria to evaluate CNS ORR called RANO-BM. It is a more stringent criteria than RECIST, which is used for systemic ORR. That is kind of the regulatory backdrop. So we walk into the agency, we have treated over 200 patients with this drug, 43 of them in the frontline setting. We have a CNS ORR by RANO-BM of 86%. 86%.

Laura PrendergastAnalyst

Can you contextualize that? What is that?

Mark VellecaCEO

Can you contextualize that? Well, for afatinib and osimertinib, which are the only drugs available for these patients, it's in the mid-30s.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day